<i id='6D123BEBF8'><strike id='6D123BEBF8'><tt id='6D123BEBF8'><pre id='6D123BEBF8'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Medicare details structure of new drug price negotiation program 
How the first Native Hawaiian psychiatrist helped diversify medicine 
How to save PrEP access — and even expand it 
Galapagos to make CAR 
Sports medicine is finally prioritizing gender equality 
Republicans love RFK Jr. What's that tell us about health in 2024? 
At least 13 dead in Texas as scorching temps continue 
FDA advisory panel to debate high blood pressure devices 
DIEP, the 'gold standard' of breast reconstruction, is under threat 
PBMs are inflating the cost of generic drugs. They must be reined in 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
FDA greenlights medical device to combat bladder issues 
Medical records are filled with copy 
Trump to be booked at notorious Fulton County Jail at center of DOJ probe 
New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum 
